Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.
Last trade$0.8363
Day change+$0.0412 (+5.18%)
Day range$0.77 – $0.875
Volume5,785,645
Market cap$201M
OpenXASE
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$202.36M
Price / earnings
—
Price / book
3.32×
Price / sales
15.47×
EV / sales
12.62×
EV / EBITDA
-6.32×
Profitability
Earnings per share
-$0.13
Return on assets
-30.37%
Return on equity
-52.96%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
6.61×
Quick ratio
6.61×
Cash ratio
4.66×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$24.39M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for LCTX, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$1.07M
$1.73M
$6.61M
$3.68M
$2.77M
$1.5M
$2.87M
$3.78M
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$1.07M
$1.73M
$6.61M
$3.68M
$2.77M
$1.5M
$2.87M
$3.78M
Selling, general and administrative
$5.22M
$5.08M
$4.85M
$4.19M
$4.56M
$4.86M
$4.4M
$4.41M
Research and development
$4.77M
$4.23M
$8.24M
$3.27M
$3.11M
$3.11M
$3.42M
$3.17M
Total operating expenses
$9.99M
$9.32M
$13.16M
$7.47M
$22.55M
$8.01M
$7.98M
$7.62M
Operating income
-$8.92M
-$7.59M
-$6.55M
-$3.79M
-$19.78M
-$6.51M
-$5.11M
-$3.84M
Interest expense
$0
$405K
$0
$0
$0
$478K
$0
$0
Income before taxes
$1.54M
-$4.79M
-$4.39M
-$29.75M
-$30.36M
-$4.14M
-$3.25M
-$3M
Income taxes
$0
$0
-$5.28M
$0
$0
$0
$0
$0
Net income
$1.54M
-$4.79M
$892K
-$29.75M
-$30.36M
-$4.14M
-$3.25M
-$3M
Net income attributable to common shareholders
$1.48M
-$4.81M
$851K
-$29.78M
-$30.46M
-$4.14M
-$3.27M
-$3.03M
EBITDA
-$8.74M
-$7.41M
-$6.36M
-$3.61M
-$4.77M
-$6.34M
-$4.96M
-$3.7M
Basic earnings per share
$0.01
-$0.02
$0.00
-$0.13
-$0.13
-$0.02
-$0.01
-$0.02
Diluted earnings per share
-$0.03
-$0.03
$0.00
-$0.13
-$0.13
-$0.02
-$0.01
-$0.02
Recent news
Company coverage with links to the original publishers.
Lineage Cell (LCTX) reported a quarterly loss of $0.03 per share, missing the consensus estimate of $0.02 loss by 50%. Revenue came in at $1.43 million, down 61% year-over-year and missing estimates by 58.71%. The stock has underperformed the S&P 500 by 44.8% year-to-date. Despite the miss, the company maintains a Zacks Rank #2 (Buy) rating based on favorable estimate revision trends ahead of the earnings release.
Cell-based therapies are emerging as a transformative approach in healthcare, with the global cell therapy market expected to grow from $4.7 billion in 2023 to over $20 billion by 2030. Several biotech companies announced significant milestones: Avaí Bio and Austrianova completed a Master Cell Bank for α-Klotho anti-aging therapy; Geron presented real-world evidence for RYTELO in myelodysplastic syndromes; BioAge Labs reported Phase 1 results for BGE-102 showing strong inflammatory biomarker reductions; Lineage Cell Therapeutics presented 3-year data for OpRegen cell therapy in geographic atrophy; and Fate Therapeutics advanced FT819 CAR T-cell therapy with FDA recognition.
The longevity biotech market is expanding rapidly, projected to grow from $9.86 billion in 2025 to $29.7 billion by 2034. Multiple companies are advancing cell and gene therapies targeting age-related diseases: Lineage Cell Therapeutics is developing islet therapy for Type 1 diabetes, Ocugen reported 46% lesion reduction in age-related macular degeneration, Vertex is advancing stem cell-derived islet therapy toward regulatory submissions, and Longeveron published positive Phase 2b data for age-related frailty treatment.
Avaí Bio announced it has initiated manufacturing of a Master Cell Bank of genetically modified cells that overexpress the α-Klotho protein, a key anti-aging protein that naturally declines by 50% after age 40. The milestone represents a transition from research to production infrastructure for their Klothonova anti-aging platform using Cell-in-a-Box® encapsulation technology. The cell therapy sector is rapidly expanding, with the global market projected to grow from $10.4 billion to over $45 billion by 2035.
The healthcare sector is experiencing a structural shift toward regenerative medicine and longevity infrastructure, valued at $27 trillion by 2030. Several biotech companies are advancing cell therapy and gene-targeted treatments: Avant Technologies presented cell encapsulation technology for diabetes at a European symposium, MannKind received FDA label updates for Afrezza inhaled insulin, Altimmune gained FDA Breakthrough Therapy Designation for pemvidutide in liver disease, Lineage Cell Therapeutics received a gene-edited cell line from Factor Bioscience, and Arrowhead Pharmaceuticals initiated a Phase 1/2a trial for a dual-gene silencing RNAi therapeutic for cardiovascular disease.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.